이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage (GEM)

2026년 7월 20일 업데이트: Lamiya Mohiyiddeen, Fakih IVF Fertility Center

A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage After IVF With PGT-A Screened Euploid Embryo Transfer

Recurrent pregnancy loss (RPL), commonly referred to as recurrent miscarriage, affects approximately 1-2% of couples attempting to conceive. In nearly half of these cases, no definitive cause can be identified despite thorough clinical evaluation. A circumstance that is both distressing and disorienting for affected families, particularly in settings such as the United Arab Emirates (UAE), where childbearing carries significant personal and cultural weight.

One leading hypothesis is that the underlying problem may not lie with the embryo itself, but with the way the mother's immune system responds to a developing pregnancy. Under normal physiological conditions, the maternal body must establish immune tolerance toward an embryo that is genetically half-foreign in origin. In some women, this tolerance mechanism may be impaired, reducing the likelihood that a pregnancy will successfully implant and progress.

This study will evaluate whether granulocyte colony-stimulating factor (G-CSF) a naturally occurring substance that normally stimulates the production of immune cells can help address this issue by modulating an overactive immune response and enhancing the uterine environment's capacity to support pregnancy. Notably, the study will enroll only women whose embryos have undergone genetic testing and been confirmed to be chromosomally normal. This eliminates embryo quality as a contributing factor to pregnancy loss and allows for a clearer assessment of whether G-CSF itself influences outcomes.

Earlier small-scale studies, including preliminary work conducted at our own centre, have shown encouraging results. This new trial builds on that foundation by enrolling a larger cohort, comparing G-CSF against a placebo (an inactive comparison treatment), and evaluating a simpler route of administration; subcutaneous injection, rather than direct infusion into the uterus. Together, these design features aim to provide the most reliable evidence to date on whether this treatment can meaningfully help couples affected by unexplained recurrent pregnancy loss.

연구 개요

상세 설명

Recurrent pregnancy loss (RPL) defined as two or more consecutive miscarriages before 20 weeks' gestation affects 1-2% of couples worldwide and remains one of the most distressing, poorly resolved conditions in reproductive medicine. In nearly half of cases, no definitive cause is identified. This burden is especially pronounced in the UAE and wider GCC region, where delayed childbearing and the strong sociocultural weight placed on fertility amplify the psychological, marital, and financial toll of unexplained RPL.

Despite decades of research, treatment remains largely empirical. Immune dysregulation is increasingly implicated as a central mechanism, with proposed pathways including aberrant natural killer (NK) cell activation, impaired regulatory T-cell expansion, inadequate decidualization, and an unfavorable Th1/Th17 cytokine profile, collectively compromising endometrial receptivity and embryo survival. However, most supporting studies have been small, uncontrolled, and unable to distinguish maternal immunological causes from embryo genetic abnormalities, leaving clinicians with few evidence-based options.

Granulocyte colony-stimulating factor (G-CSF), a hematopoietic cytokine with immunomodulatory and endometrial effects, has emerged as a promising candidate. Preclinical and early clinical data suggest it enhances endometrial proliferation and vascularization, supports folliculogenesis and oocyte competence, and promotes immune tolerance by expanding regulatory T-cells while reducing NK cell cytotoxicity. Small trials in both recurrent implantation failure and RPL populations have reported benefits in implantation and live birth rates, though results have been inconsistent - largely due to the same methodological limitations noted above, plus a failure to control for embryo aneuploidy as a confounder.

Our own retrospective pilot study of 19 patients receiving intrauterine G-CSF supports this rationale: 70.5% achieved a positive β-hCG, 66.7% progressed to ongoing pregnancy, and no adverse effects were observed. These findings demonstrate both feasibility and preliminary efficacy at our centre. However, intrauterine infusion is invasive, costly, and less patient-friendly; existing literature suggests subcutaneous administration may achieve comparable efficacy with greater convenience, but this route has not yet been evaluated in this specific population.

The GEM Trial is designed to resolve these open questions directly. By enrolling women with unexplained RPL undergoing IVF with preimplantation genetic testing for aneuploidy (PGT-A), the trial eliminates embryo chromosomal abnormality as a confounder, enabling a precise, mechanistically targeted test of the immunological hypothesis. It will be the first placebo-controlled, genetically controlled trial of G-CSF in this population, and the first to formally assess subcutaneous delivery.

If successful, the GEM Trial could establish a new standard of care for unexplained RPL offering a more convenient, evidence-based treatment option to thousands of couples and positioning the UAE as a global leader in reproductive immunology research.

연구 유형

중재적

등록 (추정된)

150

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Abu Dhabi, 아랍 에미리트
        • 모병
        • Fakih IVF Fertility Centre LLC
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Michael Fakih, MD
        • 수석 연구원:
          • Lamiya Mohiyiddeen, MD, FRCOG
        • 수석 연구원:
          • Yasmin Sajjad, MD, FRCOG

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion:

  1. Women aged 18-44 years
  2. ≥2 unexplained pregnancy losses
  3. Undergoing IVF with PGT-A tested embryos
  4. BMI 19-35 kg/m² 6.

Exclusion:

  1. Parental karyotype abnormalities
  2. Correctable uterine abnormalities
  3. Systemic autoimmune disease / thrombophilia
  4. Uncontrolled systemic illness (e.g. diabetes, infection)
  5. Previous G-CSF therapy
  6. Hypersensitivity to rhG-CSF or E. coli proteins
  7. HIV, malignancy within 5 years, or severe cardiovascular/respiratory history

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Recombinant G-CSF 130 mcg SC
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation
위약 비교기: Placebo Control: Placebo SC
Subcutaneous injection of placebo daily from embryo transfer until 12 weeks' gestation
Subcutaneous injection of Recombinant G-CSF daily from embryo transfer until 12 weeks' gestation

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Clinical pregnancy rate
기간: From enrollment to 16 weeks gestation
Clinical pregnancy confirmation by transvaginal ultrasound at 16 weeks' gestation.
From enrollment to 16 weeks gestation

2차 결과 측정

결과 측정
측정값 설명
기간
Live birth rate
기간: From enrollment to approximately 40 weeks' gestation.
From enrollment to approximately 40 weeks' gestation.
Ongoing Pregnancy Rate
기간: From 16 weeks to 34 weeks gestation.
16 - 34 weeks gestation by serial ultrasound.
From 16 weeks to 34 weeks gestation.
Early Pregnancy Loss rate
기간: From FET (Fetal Embryo Transfer) to 12 weeks gestation
Pregnancy loss confirmed by a transvaginal ultrasound.
From FET (Fetal Embryo Transfer) to 12 weeks gestation
Rate of Adverse pregnancy outcomes (APOs)
기간: From enrollment to approximately 40 weeks gestation
Rate of Miscarriage, stillbirth, neonatal outcomes (birth weight, NICU admission, congenital anomalies) and maternal outcomes assessed using several methods including transvaginal ultrasound and clinical assessment.
From enrollment to approximately 40 weeks gestation
Rate of Adverse events
기간: From enrollment up to approximately 40 weeks gestation (delivery)
Safety data including pregnancy related, fetal or maternal adverse events e.g. infections, cytopenias, hypersensitivity etc.
From enrollment up to approximately 40 weeks gestation (delivery)
Rate of immunogenicity
기간: From enrollment to up to approximately 40 weeks gestation (delivery)
Anti-drug antibody (ADA) formation (serology in subset).
From enrollment to up to approximately 40 weeks gestation (delivery)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 7월 10일

기본 완료 (추정된)

2027년 8월 10일

연구 완료 (추정된)

2027년 10월 10일

연구 등록 날짜

최초 제출

2026년 7월 14일

QC 기준을 충족하는 최초 제출

2026년 7월 20일

처음 게시됨 (실제)

2026년 7월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 20일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • FAKIH-2025-10
  • DOH/ADHRTC/2026/34566666666666 (기타 식별자: Department of Health Abu Dhabi)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다